Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of VX-440 in combination with tezacaftor and ivacaftor for cystic fibrosis
2016-000454-36Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ivacaftor and tezacaftor in cystic fibrosis (CF) (3 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Safety and tolerability. Started Oct 2016; status: completed.
02
Drugs
ivacaftortezacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2016-000454-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000454-36.